16+
Major trials tracked
Neuroscience · Live ClinicalTrials.gov data
Donanemab (Kisunla) clinical trial pipeline
The timeline below tracks the 16 largest phase 2–4 donanemab (Kisunla) trials on ClinicalTrials.gov by enrolment, 5 of them actively recruiting. The next phase 3 primary completion among them is expected Nov 2027. Refreshed daily. Add up to four competitors to compare pipelines side by side.
7
Phase 3 trials
5
Actively recruiting
Nov 2027
Next phase 3 primary completion
10,692
Participants across trials
Eli Lilly and Company
Lead sponsor by trial count
donanemab (16)13 active2017–2032
donanemab
'17
'19
'21
'23
'25
'27
'29
'31
donanemab
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)P2
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)P3
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)P2
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)P3
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)P3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)P3
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)P3
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseP3
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)P2
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).P3
ATPP2
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's DiseaseP2
ALADDINP4
ATPP2
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's DiseaseP4
REVITAA-ALZP2
Upcoming readouts
11 ahead · donanemab
Select a trial to load its full ClinicalTrials.gov record.
Key donanemab trials
Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.
Track donanemab with ComplyRx
Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.
Related drug pipelines
FAQ
- How many clinical trials are running for donanemab?
- ClinicalTrials.gov lists more than 16 phase 2–4 donanemab trials. This page tracks the 16 largest by enrolment: 7 phase 2, 7 phase 3, and 2 phase 4 among them, with 5 actively recruiting. Updated daily.
- Are there clinical trials for Kisunla?
- Kisunla is the brand name for donanemab, so donanemab trials on ClinicalTrials.gov cover it. ClinicalTrials.gov lists more than 16 phase 2–4 donanemab trials. This page tracks the 16 largest by enrolment: 7 phase 2, 7 phase 3, and 2 phase 4 among them, with 5 actively recruiting. Updated daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare donanemab against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
